These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24842525)

  • 1. Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.
    Liu HL; Sun ZM; Geng LQ; Wang XB; Ding KY; Tong J; Tang BL; Zhou CY; Yao W; Zheng CC; Song KD; Zhu XY; Wei W; Wang Y
    Bone Marrow Transplant; 2014 Aug; 49(8):1063-9. PubMed ID: 24842525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of unrelated cord blood transplantation and HLA-identical sibling peripheral blood stem cell transplantation for the treatment of adult hematological malignancies].
    Zheng CC; Zhu XY; Tang BL; Tong J; Zhang XH; Zhang L; Song KD; Geng LQ; Liu HL; Sun ZM
    Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):673-679. PubMed ID: 28954345
    [No Abstract]   [Full Text] [Related]  

  • 3. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
    Tong J; Xuan L; Sun Y; Huang D; Liu H; Zheng C; Zhu X; Tang B; Song K; Zhang X; Zhang L; Yao W; Lin D; Liu Q; Sun Z
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1541-1548. PubMed ID: 28499936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis.
    Chen YH; Xu LP; Liu DH; Chen H; Zhang XH; Han W; Wang FR; Wang JZ; Wang Y; Huang XJ; Liu KY
    Chin Med J (Engl); 2013 Jul; 126(13):2499-503. PubMed ID: 23823825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.
    Takahashi S; Ooi J; Tomonari A; Konuma T; Tsukada N; Oiwa-Monna M; Fukuno K; Uchiyama M; Takasugi K; Iseki T; Tojo A; Yamaguchi T; Asano S
    Blood; 2007 Feb; 109(3):1322-30. PubMed ID: 17038536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
    Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period.
    Konuma T; Miyao K; Nakasone H; Ouchi F; Fukuda T; Tanaka M; Ozawa Y; Ota S; Kawakita T; Uchida N; Sawa M; Katayama Y; Hiramoto N; Eto T; Ichinohe T; Atsuta Y; Kanda J;
    Cytotherapy; 2024 Aug; 26(8):910-920. PubMed ID: 38639671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
    Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.
    Tewari P; Martin PL; Mendizabal A; Parikh SH; Page KM; Driscoll TA; Malech HL; Kurtzberg J; Prasad VK
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1368-77. PubMed ID: 22326631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
    Tang B; Zheng C; Liu H; Zhu X; Geng L; Wang X; Ding K; Yao W; Tong J; Song K; Zhang L; Qiang P; Zhang X; Sun Z
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):191-5. PubMed ID: 26926370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
    Sanz J; Montoro J; Solano C; Valcárcel D; Sampol A; Ferrá C; Parody R; Lorenzo I; Montesinos P; Ortí G; Hernández-Boluda JC; Balaguer-Roselló A; Guerreiro M; Carretero C; Sanz GF; Sanz MA; Piñana JL
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):358-366. PubMed ID: 31655119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
    Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
    Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
    Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.
    Rodrigues CA; Rocha V; Dreger P; Brunstein C; Sengeloev H; Finke J; Mohty M; Rio B; Petersen E; Guilhot F; Niederwieser D; Cornelissen JJ; Jindra P; Nagler A; Fegueux N; Schoemans H; Robinson S; Ruggeri A; Gluckman E; Canals C; Sureda A; ;
    Haematologica; 2014 Feb; 99(2):370-7. PubMed ID: 23935024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.